Wells Fargo & Company MN Has $256,000 Stake in AnaptysBio Inc (ANAB)

Wells Fargo & Company MN increased its position in AnaptysBio Inc (NASDAQ:ANAB) by 92.3% in the third quarter, Holdings Channel reports. The institutional investor owned 7,326 shares of the biotechnology company’s stock after acquiring an additional 3,516 shares during the period. Wells Fargo & Company MN’s holdings in AnaptysBio were worth $256,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. New York State Common Retirement Fund raised its position in shares of AnaptysBio by 21.4% in the third quarter. New York State Common Retirement Fund now owns 8,500 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 1,500 shares during the last quarter. Teachers Advisors LLC increased its position in AnaptysBio by 23.4% during the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,807 shares during the last quarter. Alps Advisors Inc. increased its position in AnaptysBio by 10.0% during the third quarter. Alps Advisors Inc. now owns 20,034 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 1,824 shares during the last quarter. Legal & General Group Plc increased its position in AnaptysBio by 160.8% during the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 1,951 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in AnaptysBio by 89.5% during the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,776 shares during the last quarter. 75.37% of the stock is owned by institutional investors and hedge funds.

ANAB has been the subject of several research analyst reports. Jefferies Group initiated coverage on shares of AnaptysBio in a research report on Thursday, November 9th. They set a “buy” rating and a $101.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $76.00 price target (up previously from $35.00) on shares of AnaptysBio in a research report on Friday, October 13th. Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Wednesday, October 11th. SunTrust Banks initiated coverage on shares of AnaptysBio in a research report on Wednesday, November 15th. They set a “buy” rating and a $115.00 price target for the company. Finally, Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $101.89.

AnaptysBio Inc (NASDAQ ANAB) opened at $102.35 on Wednesday. AnaptysBio Inc has a 52-week low of $18.15 and a 52-week high of $126.23. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02. sell-side analysts expect that AnaptysBio Inc will post -1.69 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company MN Has $256,000 Stake in AnaptysBio Inc (ANAB)” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://transcriptdaily.com/2018/02/07/wells-fargo-company-mn-has-256000-stake-in-anaptysbio-inc-anab.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply